Laboratory Corporation of America Holdings with ticker code (LH) now have 14 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 285 and 215 and has a mean target at $250.49. Given that the stocks previous close was at $204.45 this would indicate that there is a potential upside of 22.5%. It’s also worth noting that there is a 50 day moving average of $212.90 and the 200 day MA is $203.20. The company has a market capitalization of 18.13B. The stock price for the company is currently 204.6 USD
The potential market cap would be $22,209,697,631 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.16, revenue per share of 167.11 and a 5.51% return on assets.
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
